Logo image of BRCN

BURCON NUTRASCIENCE CORP (BRCN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BRCN - CA1208311029 - Common Stock

0.44 USD
-0.02 (-4.78%)
Last: 9/9/2022, 8:00:01 PM
0.44 USD
0 (0%)
After Hours: 9/9/2022, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, BRCN scores 2 out of 10 in our fundamental rating. BRCN was compared to 82 industry peers in the Chemicals industry. BRCN may be in some trouble as it scores bad on both profitability and health. BRCN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BRCN has reported negative net income.
BRCN Yearly Net Income VS EBIT VS OCF VS FCFBRCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -43.62%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRCN Yearly ROA, ROE, ROICBRCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

Industry RankSector Rank
OM -3208.53%
PM (TTM) -4537.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRCN Yearly Profit, Operating, Gross MarginsBRCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

  • BRCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BRCN has been increased compared to 1 year ago.
  • The debt/assets ratio for BRCN is higher compared to a year ago.
BRCN Yearly Shares OutstandingBRCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
BRCN Yearly Total Debt VS Total AssetsBRCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • BRCN has an Altman-Z score of 37.52. This indicates that BRCN is financially healthy and has little risk of bankruptcy at the moment.
  • BRCN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.52
ROIC/WACCN/A
WACC8.7%
BRCN Yearly LT Debt VS Equity VS FCFBRCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M 20M 30M

2.3 Liquidity

  • BRCN has a Current Ratio of 3.16. This indicates that BRCN is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 3.16 indicates that BRCN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 3.16
BRCN Yearly Current Assets VS Current LiabilitesBRCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

  • BRCN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -416.56%.
  • Looking at the last year, BRCN shows a decrease in Revenue. The Revenue has decreased by -8.93% in the last year.
  • BRCN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.76% yearly.
EPS 1Y (TTM)-416.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.29%
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y62.45%
Revenue growth 5Y13.76%
Sales Q2Q%403.84%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.92% on average over the next years.
  • BRCN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 208.29% yearly.
EPS Next Y-26.67%
EPS Next 2Y15.47%
EPS Next 3Y8.74%
EPS Next 5Y4.92%
Revenue Next Year489.89%
Revenue Next 2Y285.85%
Revenue Next 3Y230.61%
Revenue Next 5Y208.3%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BRCN Yearly Revenue VS EstimatesBRCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
BRCN Yearly EPS VS EstimatesBRCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BRCN. In the last year negative earnings were reported.
  • Also next year BRCN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRCN Price Earnings VS Forward Price EarningsBRCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -8.09
BRCN Per share dataBRCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.47%
EPS Next 3Y8.74%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BRCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

NASDAQ:BRCN (9/9/2022, 8:00:01 PM)

After market: 0.44 0 (0%)

0.44

-0.02 (-4.78%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-15
Earnings (Next)11-14
Inst Owners6.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap47.84M
Revenue(TTM)244.05K
Net Income(TTM)-11.07M
Analysts85.45
Price Target1.67 (279.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 260.47
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB N/A
EV/EBITDA -8.09
EPS(TTM)-0.07
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.17
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -3208.53%
PM (TTM) -4537.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.16
Quick Ratio 3.16
Altman-Z 37.52
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-416.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.29%
EPS Next Y-26.67%
EPS Next 2Y15.47%
EPS Next 3Y8.74%
EPS Next 5Y4.92%
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y62.45%
Revenue growth 5Y13.76%
Sales Q2Q%403.84%
Revenue Next Year489.89%
Revenue Next 2Y285.85%
Revenue Next 3Y230.61%
Revenue Next 5Y208.3%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BURCON NUTRASCIENCE CORP / BRCN FAQ

What is the fundamental rating for BRCN stock?

ChartMill assigns a fundamental rating of 4 / 10 to BRCN.


What is the valuation status for BRCN stock?

ChartMill assigns a valuation rating of 1 / 10 to BURCON NUTRASCIENCE CORP (BRCN). This can be considered as Overvalued.


Can you provide the profitability details for BURCON NUTRASCIENCE CORP?

BURCON NUTRASCIENCE CORP (BRCN) has a profitability rating of 0 / 10.


How financially healthy is BURCON NUTRASCIENCE CORP?

The financial health rating of BURCON NUTRASCIENCE CORP (BRCN) is 8 / 10.


What is the earnings growth outlook for BURCON NUTRASCIENCE CORP?

The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BRCN) is expected to decline by -26.67% in the next year.